Matricelf has received written feedback from the U.S. Food and Drug Administration supporting several key elements of its proposed first-in-human trial for NewRal, a personalized engineered neural tissue transplant being developed for traumatic spinal cord injury. The FDA agreed that adults with chronic, complete traumatic thoracic spinal cord injury classified as AIS A represent a reasonable initial population and that a single-arm, open-label study with 12 months of initial follow-up could be appropriate for evaluating safety and tolerability. The agency also supported the company’s proposed safety assessments and exploratory neurological and functional measures, while requesting additional information on stopping rules, discharge criteria, surgical details and imaging criteria before any future Investigational New Drug application can be evaluated.
The regulatory distinction is crucial. Matricelf has not submitted or received clearance of a complete IND, NewRal has never been tested in humans, and the FDA feedback does not authorize the company to begin a clinical trial. It came through a Written Response Only interaction based on a limited clinical-trial synopsis, meaning Matricelf still needs to assemble the manufacturing, preclinical, surgical and clinical documentation required for a formal IND submission. The company explicitly states that the FDA could request additional or different information when it reviews a complete application.
What exactly is NewRal and why is it described as personalized neural tissue?
NewRal is designed around an autologous regenerative-medicine strategy. Matricelf intends to use patient-derived cellular material, including induced pluripotent stem cells, together with an extracellular-matrix-based biomaterial scaffold derived from the patient’s own tissue. The goal is to create an engineered neural tissue implant tailored to the individual patient rather than manufacturing one standardized donor-cell product for everyone.
Induced pluripotent stem cells are created by reprogramming mature cells into a state from which they can again differentiate into other cell types. In a spinal cord program, those cells can potentially be directed toward neural lineages intended to survive within or around an injured region and contribute to tissue repair, neuronal support or reconnection. Matricelf’s scaffold is intended to provide a three-dimensional environment rather than injecting a simple suspension of cells into damaged tissue.
The personalized design could theoretically reduce some immune-compatibility issues because cellular and matrix components originate from the same patient. It also makes manufacturing significantly more complicated. A therapy must be generated separately for each individual under tightly controlled conditions, and regulators need confidence that each personalized product meets identity, potency, purity and safety specifications before implantation.
Why has the FDA proposed starting with chronic AIS A thoracic spinal cord injury?
AIS A represents complete spinal cord injury under the American Spinal Injury Association Impairment Scale, meaning there is no preserved sensory or motor function in the lowest sacral segments required for classification as an incomplete injury. Selecting patients with chronic, complete injuries can help investigators distinguish treatment-related neurological changes from spontaneous recovery, which is generally more difficult to interpret soon after an acute injury.
Thoracic injuries may also provide a more controlled initial safety setting than high cervical injuries because adverse neurological changes at cervical levels can affect respiratory function and upper-extremity independence. A first-in-human regenerative procedure is primarily designed to establish whether implantation can be performed safely, whether the graft behaves as intended and whether tumor formation, abnormal growth or neurological worsening emerges.
The FDA specifically agreed that Matricelf’s proposed population of adults with chronic, complete traumatic thoracic SCI classified as AIS A is reasonable based on the limited synopsis it reviewed. That agreement does not prevent the agency from refining eligibility requirements after seeing the full IND package.
What will the proposed NewRal trial actually measure?
Matricelf proposed an open-label, single-arm trial with an initial 12-month follow-up period, and the FDA considered that framework reasonable for an initial assessment of safety and tolerability. Exploratory efficacy measures would include ISNCSCI, the Modified Ashworth Scale and SCIM III. Together, these tools assess neurological function, spasticity and independence in daily activities.
ISNCSCI provides standardized assessment of sensory and motor function after spinal cord injury, while SCIM III measures practical independence in activities particularly relevant to people with SCI. The Modified Ashworth Scale assesses resistance associated with spasticity. None of these measurements alone can prove that transplanted tissue has regenerated the cord, but improvement across neurological and functional domains could generate an early signal worthy of testing in larger controlled studies.
The FDA also made clear that this initial study should remain fundamentally a safety investigation. That is appropriate because NewRal has never been implanted in a person and because pluripotent-cell-derived therapies carry distinctive concerns including abnormal cellular proliferation, inappropriate differentiation and tumor formation.
What has Matricelf done to address tumor and biodistribution risk before human testing?
Matricelf reported completing a GLP safety study involving 248 animals followed for as long as 39 weeks after implantation. According to the company, the study met its predefined endpoints with no treatment-related toxicity, no tumor formation and no migration of implanted material to distant organs or tissues. Those results form part of the preclinical foundation for moving toward an IND, although they remain company-reported animal findings rather than evidence of human safety.
The company has also started a 96-animal IND-enabling efficacy study in a chronic spinal cord injury model. That program is evaluating motor and sensory recovery using functional, behavioral and histological measures intended to document whether the engineered tissue produces a reproducible therapeutic signal.
These animal programs are particularly important because pluripotent-cell-derived therapies can potentially form unwanted tissue if undifferentiated cells remain within the product. Regulators therefore scrutinize cell characterization, manufacturing consistency, tumorigenicity and biodistribution before exposing patients to a product that may remain in the central nervous system permanently.
Has any iPSC-derived neural therapy already been tested in people with spinal cord injury?
Yes, but the most important recent human experience comes from a completely separate Japanese program and should not be confused with NewRal. Researchers at Keio University reported a first-in-human study involving four patients with subacute complete cervical spinal cord injury who received iPSC-derived neural stem/progenitor cells. No tumor formation or graft-related adverse events were observed during two to four years of follow-up, and two participants improved from AIS A to higher grades by 52 weeks.
That study was too small and uncontrolled to establish efficacy, and its transplanted product, timing after injury and manufacturing strategy differ from Matricelf’s personalized autologous approach. Nevertheless, it provides important field-level evidence that iPSC-derived neural cells can be transplanted into an injured human spinal cord and followed long term without inevitable tumor formation. The Nature Medicine authors themselves emphasized that the observed neurological gains could not be attributed definitively to treatment because spontaneous recovery and the open-label design remained major limitations.
For Matricelf, the precedent is encouraging but not transferable. NewRal must establish its own safety, manufacturing consistency and clinical activity.
Why does Matricelf want to treat chronic rather than subacute spinal cord injury?
The chronic setting presents a much tougher regenerative challenge but also a clearer efficacy experiment. Soon after an injury, inflammation, edema and spontaneous neurological recovery can continue for months, making it difficult to determine whether improvement comes from a therapy or natural healing. In chronic complete injury, neurological status is generally more stable, so a meaningful new change can be more informative.
The disadvantage is that chronic spinal cord injury contains established scar tissue, disrupted neural architecture and a biological environment less naturally supportive of regeneration. A successful implant would need not merely protect injured neurons during an acute phase but help establish useful tissue or connectivity after the original injury has stabilized.
That is one reason NewRal’s engineered-tissue concept is ambitious. Matricelf is not simply delivering a soluble growth factor. It is attempting to implant a structured biological product intended to integrate with an area where normal neural continuity has been lost.
What additional information did the FDA ask Matricelf to provide?
The agency requested explicit trial stopping rules, objective criteria governing when patients can be discharged after surgery, further details of the implantation procedure and imaging criteria used to select candidates. These requests reflect the combined risks of a cellular product and a neurosurgical intervention.
Stopping rules determine when unexpected toxicity should pause enrollment before additional participants are exposed. Discharge criteria help ensure patients remain under observation long enough after surgery, while imaging criteria are needed to identify injuries anatomically suitable for implantation. Surgical detail is particularly important because safety can depend as much on the delivery procedure as on the biological product itself.
The requests therefore should not be interpreted as regulatory obstacles unique to NewRal. They are exactly the kinds of operational details regulators need before permitting first exposure of a novel engineered tissue to humans.
When could the first NewRal patient actually be treated?
There is no authorized human dosing date yet. Matricelf must complete its remaining IND-enabling work, incorporate FDA comments, prepare the full IND and wait for the agency to determine whether the proposed study may proceed. The company’s September release explicitly states that there is no assurance the IND will be submitted, accepted without additional requests or allowed to become effective on Matricelf’s preferred timetable.
That caution is worth preserving because early regenerative-medicine milestones can easily be misread as clinical success. NewRal has crossed an important regulatory-planning milestone, not a human-efficacy milestone. Its most meaningful achievement so far is that the FDA has found several core elements of the proposed first trial reasonable enough to guide the company toward a formal application.
If that IND is eventually allowed to proceed, the first patients would represent a major transition for Matricelf from animal studies and personalized manufacturing development into human regenerative medicine. The immediate question is not whether NewRal restores walking. It is whether patient-derived engineered neural tissue can be manufactured consistently, implanted safely into a chronically injured spinal cord and remain biologically controlled long enough to justify asking the efficacy question later.
